Xenograft models have long been the gold standard method for preclinically assessing the relationship between PK/PD and efficacy. However,
CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities
State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services Cambridge,
CN Bio appoints Dr Paul Brooks as Chief Business Officer
Cambridge, UK, 24 May 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ
CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit
First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and
PhysioMimix™ Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021′
Next generation Organ-on-a-Chip technology listed second in Top 10 Innovations for 2021 System enables pre-clinical studies that simulate complex
CN Bio and iiCON announce COVID-19 research collaboration
Partnership focused on validation of novel Organ-on-a-Chip infection models Human-relevant single and multi-organ SARS-CoV-2 infected models
CN Bio expands service offering to support oncology drug discovery
New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix™ PK system
CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect
Lonza and CN Bio Announce Distribution Agreement
Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range Through a new